Switch theme
Sign up to access all valuation multiples
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2.
2006
20
LTM Revenue $302M
LTM EBITDA n/a
$215M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioStem Technologies has a last 12-month revenue of $302M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, BioStem Technologies achieved revenue of $16.7M and an EBITDA of -$6.9M.
BioStem Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioStem Technologies valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.9M | $16.7M | XXX | XXX | XXX |
| Gross Profit | $2.8M | $6.0M | XXX | XXX | XXX |
| Gross Margin | 41% | 36% | XXX | XXX | XXX |
| EBITDA | -$6.4M | -$6.9M | XXX | XXX | XXX |
| EBITDA Margin | -93% | -42% | XXX | XXX | XXX |
| Net Profit | -$1.4M | -$7.1M | XXX | XXX | XXX |
| Net Margin | -20% | -42% | XXX | XXX | XXX |
| Net Debt | $4.7M | $4.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BioStem Technologies's stock price is $13.
BioStem Technologies has current market cap of $210M, and EV of $215M.
See BioStem Technologies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $215M | $210M | XXX | XXX | XXX | XXX | $1.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BioStem Technologies has market cap of $210M and EV of $215M.
BioStem Technologies's trades at 0.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate BioStem Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BioStem Technologies and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $215M | XXX | XXX | XXX |
| EV/Revenue | 12.9x | XXX | XXX | XXX |
| EV/EBITDA | -31.0x | XXX | XXX | XXX |
| P/E | -26.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -57.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBioStem Technologies's NTM/LTM revenue growth is -100%
BioStem Technologies's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, BioStem Technologies's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BioStem Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BioStem Technologies and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 143% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -42% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 72% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 60% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 135% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioStem Technologies acquired XXX companies to date.
Last acquisition by BioStem Technologies was XXXXXXXX, XXXXX XXXXX XXXXXX . BioStem Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BioStem Technologies founded? | BioStem Technologies was founded in 2006. |
| Where is BioStem Technologies headquartered? | BioStem Technologies is headquartered in United States of America. |
| How many employees does BioStem Technologies have? | As of today, BioStem Technologies has 20 employees. |
| Is BioStem Technologies publicy listed? | Yes, BioStem Technologies is a public company listed on PINX. |
| What is the stock symbol of BioStem Technologies? | BioStem Technologies trades under BSEM ticker. |
| When did BioStem Technologies go public? | BioStem Technologies went public in 2008. |
| Who are competitors of BioStem Technologies? | Similar companies to BioStem Technologies include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of BioStem Technologies? | BioStem Technologies's current market cap is $210M |
| What is the current revenue of BioStem Technologies? | BioStem Technologies's last 12-month revenue is $302M. |
| What is the current EV/Revenue multiple of BioStem Technologies? | Current revenue multiple of BioStem Technologies is 0.7x. |
| What is the current revenue growth of BioStem Technologies? | BioStem Technologies revenue growth between 2023 and 2024 was 143%. |
| Is BioStem Technologies profitable? | Yes, BioStem Technologies is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
